Mohit Bansal
Stock Analyst at Wells Fargo
(4.26)
# 398
Out of 5,141 analysts
197
Total ratings
68.14%
Success rate
9.47%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $65 → $75 | $70.98 | +5.66% | 8 | Feb 19, 2026 | |
| AMGN Amgen | Maintains: Equal-Weight | $325 → $375 | $374.75 | +0.07% | 13 | Feb 19, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $70 → $75 | $64.08 | +17.04% | 7 | Feb 18, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $180 → $175 | $128.63 | +36.05% | 8 | Feb 13, 2026 | |
| GILD Gilead Sciences | Maintains: Overweight | $150 → $165 | $151.40 | +8.98% | 14 | Feb 11, 2026 | |
| BIIB Biogen | Maintains: Equal-Weight | $190 → $200 | $192.03 | +4.15% | 16 | Feb 9, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $55 → $60 | $60.66 | -1.09% | 11 | Feb 6, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,200 → $1,280 | $1,009.52 | +26.79% | 19 | Feb 5, 2026 | |
| MRK Merck & Co. | Maintains: Overweight | $125 → $135 | $122.26 | +10.42% | 13 | Feb 4, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Equal-Weight | $745 → $800 | $779.67 | +2.61% | 22 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $5 | $3.96 | +26.26% | 6 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $1.70 | +370.59% | 2 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $515 | $476.90 | +7.99% | 12 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $235 | $172.19 | +36.48% | 3 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $27.88 | +97.27% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $260 | $224.81 | +15.65% | 10 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $35 | $30.39 | +15.17% | 5 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $150 | $110.15 | +36.18% | 2 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $47 | $42.23 | +11.30% | 2 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $15.94 | +88.21% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $41.76 | +67.62% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $26.65 | +12.57% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $29.04 | +6,356.61% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $4.01 | +797.76% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $9.03 | +110.41% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.16 | +5,072.41% | 4 | Dec 3, 2019 |
Halozyme Therapeutics
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $65 → $75
Current: $70.98
Upside: +5.66%
Amgen
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $325 → $375
Current: $374.75
Upside: +0.07%
BioMarin Pharmaceutical
Feb 18, 2026
Maintains: Overweight
Price Target: $70 → $75
Current: $64.08
Upside: +17.04%
Neurocrine Biosciences
Feb 13, 2026
Maintains: Overweight
Price Target: $180 → $175
Current: $128.63
Upside: +36.05%
Gilead Sciences
Feb 11, 2026
Maintains: Overweight
Price Target: $150 → $165
Current: $151.40
Upside: +8.98%
Biogen
Feb 9, 2026
Maintains: Equal-Weight
Price Target: $190 → $200
Current: $192.03
Upside: +4.15%
Bristol-Myers Squibb Company
Feb 6, 2026
Maintains: Equal-Weight
Price Target: $55 → $60
Current: $60.66
Upside: -1.09%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $1,200 → $1,280
Current: $1,009.52
Upside: +26.79%
Merck & Co.
Feb 4, 2026
Maintains: Overweight
Price Target: $125 → $135
Current: $122.26
Upside: +10.42%
Regeneron Pharmaceuticals
Feb 2, 2026
Maintains: Equal-Weight
Price Target: $745 → $800
Current: $779.67
Upside: +2.61%
Jan 5, 2026
Maintains: Equal-Weight
Price Target: $3 → $5
Current: $3.96
Upside: +26.26%
Dec 16, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $1.70
Upside: +370.59%
Dec 10, 2025
Maintains: Overweight
Price Target: $460 → $515
Current: $476.90
Upside: +7.99%
Nov 18, 2025
Maintains: Overweight
Price Target: $170 → $235
Current: $172.19
Upside: +36.48%
Nov 11, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $27.88
Upside: +97.27%
Sep 12, 2025
Maintains: Overweight
Price Target: $240 → $260
Current: $224.81
Upside: +15.65%
Sep 11, 2025
Maintains: Overweight
Price Target: $27 → $35
Current: $30.39
Upside: +15.17%
Aug 5, 2025
Maintains: Overweight
Price Target: $170 → $150
Current: $110.15
Upside: +36.18%
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $42.23
Upside: +11.30%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $15.94
Upside: +88.21%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $41.76
Upside: +67.62%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $26.65
Upside: +12.57%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $29.04
Upside: +6,356.61%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $4.01
Upside: +797.76%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $9.03
Upside: +110.41%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.16
Upside: +5,072.41%